TaiGen Biopharmaceuticals Holdings Limited Return on Equity

TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) currently reports a ROE of 15.17%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore TaiGen Biopharmaceuticals Holdings Limited's ROE history and peer comparisons.

TaiGen Biopharmaceuticals Holdings Limited's ROE of 15.17% is higher than the Healthcare sector average of 11.15%. That is roughly 36.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but TaiGen Biopharmaceuticals Holdings Limited's current 15.17% should be judged against Healthcare norms (sector average: 11.15%) and against 4157.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 15.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for TaiGen Biopharmaceuticals Holdings Limited, and consider following 4157.TWO for alerts when major investors trade the stock.

TaiGen Biopharmaceuticals Holdings Limited is classified in the Healthcare sector. On ROE, it currently shows 15.17% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4157.TWO with unrelated industries.